US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Cyclosporine 1% Human Eye Drops

Reason Lack of Process Controls

Westlab Pharmacy, Inc. dba Westlab Pharmacy NDC 10002-2776-92 D-0091-2019
Class II · Moderate risk Terminated

ADAA Cataract Drops

Reason Lack of Process Controls

Westlab Pharmacy, Inc. dba Westlab Pharmacy NDC 10002-2579-05 D-0090-2019
Class II · Moderate risk Terminated

Alprostadil 500 mcg/mL Injectable

Reason Incorrect Product Formulation

Westlab Pharmacy, Inc. dba Westlab Pharmacy NDC 10002-7335-00 D-0089-2019
Class III · Low risk Terminated

Contrave

Reason Defective Container: Customer complaints of punctures in the bottle.

Orexigen Therapeutics, Inc. NDC 51267-890-99 D-1099-2018
Class III · Low risk Terminated

Azelastine HCl Ophthalmic Solution 0.05%

Reason Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide

Akorn, Inc. NDC 17478-718-10 D-1168-2018
Class III · Low risk Terminated

Diltiazem HCl Extended-Release Capsules

Reason Failed Impurities/Degradation Specifications: Out of specification test results obtained during routine stability testing for related compound.

Mylan Pharmaceuticals Inc. NDC 0378-5220-05 D-1187-2018
Class III · Low risk Terminated

Diltiazem HCl Extended-Release Capsules

Reason Failed Impurities/Degradation Specifications: Out of specification test results obtained during routine stability testing for related compound.

Mylan Pharmaceuticals Inc. NDC 0378-5220-01 D-1186-2018
Class II · Moderate risk Terminated

Doxycycline Hyclate USP Tablets

Reason Failed Dissolution Specifications: manufacturer West-Ward Pharm Corp. recalled these repackaged lots due to failed dissolution results.

PD-Rx Pharmaceuticals, Inc. NDC 55289-866-02 D-1127-2018
Class II · Moderate risk Terminated

PIO&METFORMIN 15/1000 mg Tab 1

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA D-0102-2019
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended Release Tablets 1000 mg

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA NDC 00591-2412-19 D-0101-2019
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended Release Tablets 1000 mg

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA NDC 00591-2720-60 D-0100-2019
Class II · Moderate risk Terminated

Metformin Hydrochloride Extended Release Tablets

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA NDC 00591-2411-01 D-0099-2019
Class II · Moderate risk Terminated

Fortamet

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA NDC 59630-575-60 D-0098-2019
Class II · Moderate risk Terminated

Paliperidone Extended Release Tablets 9 mg

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA NDC 0591-3695-30 D-0097-2019
Class II · Moderate risk Terminated

Paliperidone Extended Release Tablets 3 mg

Reason Defective Delivery System: There is a potential for some tablets to be missing the laser drilling which might affect drug release.

Teva Pharmaceuticals USA NDC 0591-3693-30 D-0096-2019
Class I · High risk Terminated

Levothyroxine and Liothyronine

Reason Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.

Westminster Pharmaceuticals LLC NDC 69367-158-04 D-1182-2018
Class I · High risk Terminated

Levothyroxine and Liothyronine

Reason Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.

Westminster Pharmaceuticals LLC NDC 69367-159-04 D-1181-2018
Class I · High risk Terminated

Levothyroxine and Liothyronine

Reason Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.

Westminster Pharmaceuticals LLC NDC 69367-155-04 D-1180-2018
Class I · High risk Terminated

Levothyroxine and Liothyronine

Reason Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.

Westminster Pharmaceuticals LLC NDC 69367-157-04 D-1179-2018
Class I · High risk Terminated

Levothyroxine and Liothyronine

Reason Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.

Westminster Pharmaceuticals LLC NDC 69367-156-04 D-1178-2018
Class III · Low risk Terminated

Acne Treatment Pads

Reason Subpotent drug: The product active ingredient level not matching the exact levels indicated on the packaging label.

Huijing (Shanghai) Bio-tech Co., Ltd. NDC 71537-001-02 D-1076-2018
Class II · Moderate risk Terminated

Family Dollar Saline Nasal Spray 4.25 oz. can

Reason CGMP Deviations: products manufactured under conditions that could impact its product quality.

Product Quest Manufacturing LLC D-0080-2019
Class II · Moderate risk Terminated

Finafta Baby

Reason CGMP Deviations: products manufactured under conditions that could impact its product quality.

Product Quest Manufacturing LLC D-0079-2019
Class II · Moderate risk Terminated

Rexall

Reason CGMP Deviations: products manufactured under conditions that could impact its product quality.

Product Quest Manufacturing LLC D-0078-2019
Class II · Moderate risk Terminated

Rexall

Reason CGMP Deviations: products manufactured under conditions that could impact its product quality.

Product Quest Manufacturing LLC D-0077-2019